BCR-ABL1 compound mutations in tyrosine kinase inhibitor–resistant CML: frequency and clonal relationships

BCR-ABL1 compound mutations can confer high-level resistance to imatinib and other ABL1 tyrosine kinase inhibitors (TKIs). The third-generation ABL1 TKI ponatinib is effective against BCR-ABL1 point mutants individually, but remains vulnerable to certain BCR-ABL1 compound mutants. To determine the f...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Khorashad, Jamshid S., Kelley, Todd W., Szankasi, Philippe, Mason, Clinton C., Soverini, Simona, Adrian, Lauren T., Eide, Christopher A., Zabriskie, Matthew S., Lange, Thoralf, Estrada, Johanna C., Pomicter, Anthony D., Eiring, Anna M., Kraft, Ira L., Anderson, David J., Gu, Zhimin, Alikian, Mary, Reid, Alistair G., Foroni, Letizia, Marin, David, Druker, Brian J., O'Hare, Thomas, Deininger, Michael W.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2013
Matèries:
Myeloid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3548169/
https://ncbi.nlm.nih.gov/pubmed/23223358
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-05-431379
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars